Annual EBITDA
-$46.05 M
+$4.44 M+8.79%
December 31, 2023
Summary
- As of February 20, 2025, CUE annual EBITDA is -$46.05 million, with the most recent change of +$4.44 million (+8.79%) on December 31, 2023.
- During the last 3 years, CUE annual EBITDA has fallen by -$1.01 million (-2.24%).
- CUE annual EBITDA is now -2344.50% below its all-time high of -$1.88 million, reached on December 31, 2015.
Performance
CUE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$7.59 M
+$1.50 M+16.48%
September 30, 2024
Summary
- As of February 20, 2025, CUE quarterly EBITDA is -$7.59 million, with the most recent change of +$1.50 million (+16.48%) on September 30, 2024.
- Over the past year, CUE quarterly EBITDA has increased by +$1.50 million (+16.48%).
- CUE quarterly EBITDA is now -285.96% below its all-time high of -$1.97 million, reached on September 30, 2016.
Performance
CUE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$40.02 M
+$2.27 M+5.36%
September 30, 2024
Summary
- As of February 20, 2025, CUE TTM EBITDA is -$40.02 million, with the most recent change of +$2.27 million (+5.36%) on September 30, 2024.
- Over the past year, CUE TTM EBITDA has increased by +$2.27 million (+5.36%).
- CUE TTM EBITDA is now -1933.84% below its all-time high of -$1.97 million, reached on September 30, 2016.
Performance
CUE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CUE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.8% | +16.5% | +5.4% |
| 3 y3 years | -2.2% | +44.4% | +20.7% |
| 5 y5 years | -21.4% | +44.4% | +20.7% |
CUE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -5.5% | +8.8% | at high | +45.8% | -1.8% | +20.7% |
| 5 y | 5-year | -28.1% | +8.8% | at high | +45.8% | -13.6% | +20.7% |
| alltime | all time | -2344.5% | +8.8% | -286.0% | +45.8% | -1933.8% | +20.7% |
Cue Biopharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.59 M(-16.5%) | -$40.02 M(-5.4%) |
| Jun 2024 | - | -$9.09 M(-19.2%) | -$42.29 M(-6.6%) |
| Mar 2024 | - | -$11.26 M(-6.8%) | -$45.30 M(-1.3%) |
| Dec 2023 | -$46.05 M(-8.8%) | -$12.08 M(+22.4%) | -$45.90 M(-3.3%) |
| Sep 2023 | - | -$9.86 M(-18.5%) | -$47.48 M(-0.9%) |
| Jun 2023 | - | -$12.10 M(+2.1%) | -$47.91 M(-0.9%) |
| Mar 2023 | - | -$11.86 M(-13.1%) | -$48.35 M(-4.2%) |
| Dec 2022 | -$50.49 M(+15.6%) | -$13.65 M(+32.7%) | -$50.49 M(+12.9%) |
| Sep 2022 | - | -$10.29 M(-18.0%) | -$44.73 M(-2.7%) |
| Jun 2022 | - | -$12.54 M(-10.4%) | -$45.96 M(+11.7%) |
| Mar 2022 | - | -$14.00 M(+77.5%) | -$41.13 M(+4.6%) |
| Dec 2021 | -$43.67 M(-3.1%) | -$7.89 M(-31.5%) | -$39.31 M(-7.3%) |
| Sep 2021 | - | -$11.52 M(+49.4%) | -$42.40 M(+4.1%) |
| Jun 2021 | - | -$7.71 M(-36.7%) | -$40.74 M(-6.8%) |
| Mar 2021 | - | -$12.19 M(+11.0%) | -$43.69 M(-1.2%) |
| Dec 2020 | -$45.04 M | -$10.97 M(+11.3%) | -$44.24 M(+5.1%) |
| Sep 2020 | - | -$9.86 M(-7.6%) | -$42.07 M(+7.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2020 | - | -$10.67 M(-16.2%) | -$39.11 M(+3.6%) |
| Mar 2020 | - | -$12.73 M(+44.5%) | -$37.74 M(+7.1%) |
| Dec 2019 | -$35.96 M(-5.2%) | -$8.81 M(+27.7%) | -$35.23 M(-5.3%) |
| Sep 2019 | - | -$6.90 M(-25.8%) | -$37.18 M(-13.2%) |
| Jun 2019 | - | -$9.30 M(-9.0%) | -$42.85 M(+5.0%) |
| Mar 2019 | - | -$10.22 M(-5.0%) | -$40.83 M(+7.6%) |
| Dec 2018 | -$37.94 M(+66.3%) | -$10.76 M(-14.3%) | -$37.96 M(+1.2%) |
| Sep 2018 | - | -$12.56 M(+72.7%) | -$37.51 M(+25.6%) |
| Jun 2018 | - | -$7.28 M(-1.1%) | -$29.85 M(+11.0%) |
| Mar 2018 | - | -$7.36 M(-28.7%) | -$26.89 M(+17.8%) |
| Dec 2017 | -$22.81 M(+206.0%) | -$10.31 M(+110.1%) | -$22.81 M(+49.3%) |
| Sep 2017 | - | -$4.91 M(+13.8%) | -$15.28 M(+23.8%) |
| Jun 2017 | - | -$4.31 M(+31.3%) | -$12.34 M(+53.7%) |
| Mar 2017 | - | -$3.28 M(+18.1%) | -$8.03 M(+69.1%) |
| Dec 2016 | -$7.46 M(+295.8%) | -$2.78 M(+41.3%) | -$4.75 M(+141.3%) |
| Sep 2016 | - | -$1.97 M | -$1.97 M |
| Dec 2015 | -$1.88 M | - | - |
FAQ
- What is Cue Biopharma annual EBITDA?
- What is the all time high annual EBITDA for Cue Biopharma?
- What is Cue Biopharma annual EBITDA year-on-year change?
- What is Cue Biopharma quarterly EBITDA?
- What is the all time high quarterly EBITDA for Cue Biopharma?
- What is Cue Biopharma quarterly EBITDA year-on-year change?
- What is Cue Biopharma TTM EBITDA?
- What is the all time high TTM EBITDA for Cue Biopharma?
- What is Cue Biopharma TTM EBITDA year-on-year change?
What is Cue Biopharma annual EBITDA?
The current annual EBITDA of CUE is -$46.05 M
What is the all time high annual EBITDA for Cue Biopharma?
Cue Biopharma all-time high annual EBITDA is -$1.88 M
What is Cue Biopharma annual EBITDA year-on-year change?
Over the past year, CUE annual EBITDA has changed by +$4.44 M (+8.79%)
What is Cue Biopharma quarterly EBITDA?
The current quarterly EBITDA of CUE is -$7.59 M
What is the all time high quarterly EBITDA for Cue Biopharma?
Cue Biopharma all-time high quarterly EBITDA is -$1.97 M
What is Cue Biopharma quarterly EBITDA year-on-year change?
Over the past year, CUE quarterly EBITDA has changed by +$1.50 M (+16.48%)
What is Cue Biopharma TTM EBITDA?
The current TTM EBITDA of CUE is -$40.02 M
What is the all time high TTM EBITDA for Cue Biopharma?
Cue Biopharma all-time high TTM EBITDA is -$1.97 M
What is Cue Biopharma TTM EBITDA year-on-year change?
Over the past year, CUE TTM EBITDA has changed by +$2.27 M (+5.36%)